Skip to Primary Navigation

Skip to main content

Pfizer receives PMCPA censure for providing business-class flights to UK HCPs

The Pfizer logo on the side of the pharmaceutical company's corporate headquarters.
Photo: Smith Collection/Gado/Getty Images

Kevin Kinsella

4 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Ruling reinforces long‑standing Code of Practice expectations on appropriate hospitality, certification, and standards across the pharmaceutical industry.

The UK’s Prescription Medicines Code of Practice Authority (PMCPA) issued its final resolution in a 2025 case following a voluntary admission by Pfizer, concluding that the company failed to maintain high standards, certify required materials, and ensure appropriate hospitality.

The PMCPA case identifies multiple breaches of the Association of

, , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience